Cargando…

Benefits of combined treatments using antiresorptive agents and cytotoxic drugs

Detalles Bibliográficos
Autores principales:	Holen, I, Neville-Webbe, H, Coleman, RE
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3300247/ http://dx.doi.org/10.1186/bcr1555

Ejemplares similares

Synergistic effects of cytotoxic drugs and antiresorptive agents in vitro and in vivo
por: Ottewell, PD, et al.
Publicado: (2006)

Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction
por: Neville-Webbe, H L, et al.
Publicado: (2010)

Effects of combined treatment with Zometa and Taxol on endothelial cells in vitro
por: Michailidou, M, et al.
Publicado: (2006)

Targeting the tumour microenvironment: denosumab, a new RANKL inhibitor
por: Coleman, RE
Publicado: (2009)

Cytotoxic diagnostic assays are effective in drug-induced maculopapular exanthemas
por: Porebski, Grzegorz, et al.
Publicado: (2015)

Combination therapy of anabolic and nonbisphosphonates antiresorptive agents for the treatment of osteoporosis: A meta-analysis
por: Lou, Shenghan, et al.
Publicado: (2017)

Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents
por: Rodriguez-Lozano, Francisco-Javier, et al.
Publicado: (2016)

Combination Therapy of PTH and Antiresorptive Drugs on Osteoporosis: A Review of Treatment Alternatives
por: Zhang, Chenggui, et al.
Publicado: (2021)

Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk
por: Eastell, Richard, et al.
Publicado: (2022)

Antimalarial drug discovery: targeting the hypnozoite for new radical curative agent
por: Yeung, Bryan
Publicado: (2012)

Controversial Issue Session: Brace treatment in infantile scoliosis: benefits
por: Claude de Mauroy, Jean
Publicado: (2012)

Pretreatment of breast cancer cells with doxorubicin facilitates the subsequent uptake of zoledronic acid
por: Lefley, DV, et al.
Publicado: (2008)

Mechanisms of apoptosis and cell-cycle arrest in subcutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid
por: Ottewell, PD, et al.
Publicado: (2008)

Gingival cell growth with antiresorptive treatment combined with corticosteroids or antiestrogen
por: Ekholm, Heidi M., et al.
Publicado: (2021)

Can ultrasound contrast agents increase the treatment envelope?
por: McDannold, Nathan, et al.
Publicado: (2015)

No benefit of the combination therapy etanercept and methotrexate compared to etanercept mono therapy in juvenile idiopathic arthritis – a matched pair analysis
por: Schmeling, Heinrike, et al.
Publicado: (2012)

Irisin and the therapeutic benefits of exercise
por: Spiegelman, Bruce M, et al.
Publicado: (2012)

Effectiveness of anti-TNF-α agents in the treatment of refractory juvenile dermatomyositis
por: Boulter, EL, et al.
Publicado: (2011)

Benefits of using heated egg (HE) in the management of egg allergy
por: Claver, A, et al.
Publicado: (2013)

Prediction of treatment benefit in high-dimensional cox models via gene signatures in randomized clinical trials
por: Ternès, Nils, et al.
Publicado: (2015)

Disulfiram Attenuates Osteoclast Differentiation In Vitro: A Potential Antiresorptive Agent
por: Ying, Hua, et al.
Publicado: (2015)

Benefits from using recycling red blood cells in cardiovascular surgery
por: Almeida, R, et al.
Publicado: (2013)

Analysis of Serum Proteome after Treatment of Osteoporosis with Anabolic or Antiresorptive Drugs
por: del Real, Alvaro, et al.
Publicado: (2022)

Romosozumab and antiresorptive treatment: the importance of treatment sequence
por: Cosman, Felicia, et al.
Publicado: (2022)

Classical versus new prognostic factors for adjuvant treatment selection based on line software to estimate risk and benefit
por: Ravdin, PM
Publicado: (2005)

Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011)

Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy
por: Leder, Benjamin Z
Publicado: (2018)

Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models
por: Paton‐Hough, Julia, et al.
Publicado: (2018)

Adult scoliosis treatment combining brace and exercises
por: Papadopoulos, Dimitris
Publicado: (2013)

Benefits of early aneurysm surgery: Southern Iran experience
por: Rahmanian, Abdolkarim, et al.
Publicado: (2012)

In Vitro Cytotoxicity of Antiresorptive and Antiangiogenic Compounds on Oral Tissues Contributing to MRONJ: Systematic Review
por: Guirguis, Robert H., et al.
Publicado: (2023)

A novel measure of treatment benefit for an ordinal scale: a case study of the IST-1 and the IST-3 stroke trials
por: Thompson, Douglas, et al.
Publicado: (2013)

New agents for bone metastasis
por: Hortobagyi, GN
Publicado: (2005)

S101: COMBINATION OF A LUSPATERCEPT-LIKE DRUG (RAP-GRL) AND TMPRSS6-ASO IS SUPERIOR TO EITHER DRUG ALONE FOR CORRECTING β-THALASSEMIA
por: Guerra, A., et al.
Publicado: (2022)

Benefits of non-medical prescribing within an NHS podiatry service
por: Popadiuk, Susan, et al.
Publicado: (2010)

Benefits of PDE5 inhibition in patients with diastolic heart failure
por: Guazzi, Marco
Publicado: (2011)

Developed-developing country partnerships: benefits from South to North?
por: Syed, SB, et al.
Publicado: (2011)

Health benefits from moderate drinking: a critical review
por: Andreasson, Sven, et al.
Publicado: (2015)

Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome
por: Choodari-Oskooei, Babak, et al.
Publicado: (2013)

Autophagy: the pathogenic agent in muscle damage
por: Raben, Nina
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vb36ri96ahp35l7d6k2tgr5s2v